SITC Scientific Publications News

In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “ SITC Living Guidelines ” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and incorporate the ...
0 comments
In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “ SITC Living Guidelines ” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and incorporate the leading ...
0 comments
On behalf of the Society for Immunotherapy of Cancer (SITC), the SITC Biomarkers Committee, the SITC Pathology Committee, and the 2024 SITC Clinical Immuno-Oncology Network ( SCION ) faculty, we are pleased to announce the publication of a commentary on measurement and interpretation of essential biomarkers in early clinical trials . Immunotherapy of cancer is now a mainstay of modern oncologic practice and is being integrated with conventional ...
0 comments
On behalf of the society and the SITC Intratumoral Immunotherapy Clinical Trials Manuscript Development Group, we are pleased to announce the publication of a new manuscript “ Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from pre-malignant to metastatic disease ” in the Journal for ImmunoTherapy of Cancer . While intratumoral immunotherapies have the potential to boost anti-tumor ...
0 comments
Dr. Michael T. Lotze is Incoming Editor-in-Chief for the Journal for ImmunoTherapy of Cancer ( JITC ). As he transitions into his role with JITC , learn more about Dr. Lotze’s career, interest in JITC , and personal life. Career What inspired you to become a researcher? Dr. Lotze: My earliest experiences in research were a disaster; I worked on a project at Northwestern University over the summer after ...
0 comments
SITC 2024 Advances in Cancer Immunotherapy Series We’re excited to announce SITC’s 2024 Advances in Cancer Immunotherapy (ACI) educational series, which offers in-depth clinical training in immunotherapy treatment for a variety of disease states and topics from experts in the field. The ACI programs aim to engage practicing clinical oncologists, advanced practitioners, nurses, pharmacists, emergency physicians, and other allied health professionals ...
0 comments
On behalf of the Society for Immunotherapy of Cancer (SITC) and the SITC Melanoma Guideline Expert Panel, we are pleased to announce the publication of SITC’s Melanoma Clinical Practice Guideline (CPG), version 3.0. This manuscript is SITC’s first CPG covering immunotherapy indications for cutaneous melanoma as well as rarer subtypes of the disease. Immunotherapy is a standard of care option for both BRAF -wildtype and BRAFV600 -mutated ...
0 comments
On behalf of the Society for Immunotherapy of Cancer (SITC) and the International Bladder Cancer Group (IBCG), we are pleased to announce the publication of the “ Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group ,” in the Journal of Clinical Oncology. These recommendations provide a detailed clinical trial design guide ...
0 comments
On behalf of the Society for Immunotherapy of Cancer (SITC) and the SITC Gynecologic Cancer Immunotherapy Guideline Expert Panel, we are pleased to announce the publication of SITC’s Gynecologic Cancer Clinical Practice Guideline (CPG). This manuscript is SITC’s first CPG covering immunotherapy indications for cervical, endometrial, and ovarian cancer, as well as other rare gynecologic cancers. The treatment landscape in gynecologic cancers is ...
0 comments
SITC is pleased to announce the publication of our newest guideline, " Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer. " Clinicians will find this guideline an invaluable resource to assist in navigating the challenging issues that sometimes arise during the treatment of gastrointestinal cancer, including treatment selection based on histology and biomarker status, ...
0 comments
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of several solid tumors, providing deep and durable responses for many patients. However, the anti-tumor mechanism of action of ICIs can also cause aberrantly active self-damaging immune responses, leading to immune-related adverse events (irAEs). The natural history, response to treatment, and patterns of irAEs vary widely, ranging from short-term inflammatory conditions to prolonged ...
0 comments
The Society for Immunotherapy of Cancer (SITC) hosted the "Combination Immunotherapy Resistance Workshop" with the purpose of bringing together immunotherapy experts from across academia, government, and industry to reach consensus on definitions of IO resistance to accelerate drug development. Consensus resistance definitions from the workshop have recently been published in the Journal for ImmunoTherapy of Cancer ( JITC ) via three manuscripts, ...
0 comments
JITC is proud to announce the first publications in a new series, “Liquid Biopsies Coming of Age: Biology, Emerging Technologies, and Clinical Translation.” Authored by leading voices in cancer biology, technology development, and immuno-oncology, this JITC series features authoritative review articles on liquid biopsy- and ctDNA-related uses in immuno-oncology, with accompanying clinically-focused viewpoint letters from expert physicians. ...
0 comments
JITC’s complete special series of review articles, Imaging and Immunotherapy, is now available. Edited by Elisabeth G.E. de Vries, MD, PhD, and Lawrence H. Schwartz, MD, and authored by leading voices from a multitude of backgrounds, this series explores novel imaging strategies, new approaches to conventional imaging – including the use of artificial intelligence, radiomics, and MRI – and special considerations for radiotherapy, immunotherapy, ...
0 comments
The oncology community understands the need to ensure participants in clinical trials represent the broader patient community that will ultimately be treated using the therapies under investigation. The Food & Drug Administration (FDA) released draft guidance, Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Subgroups in Clinical Trials, which recommends that all sponsors submit a Race and Diversity ...
0 comments
The 37th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2022) was our largest annual meeting ever! If you attended in person or virtually, we hope you enjoyed the world’s largest conference focused solely on cancer immunotherapy. Abstracts are available in JITC .
0 comments
No uniform method has been established to predict the probability of success for individual clinical trials. To help identify clinical trials with a high likelihood of offering benefit to patients, the Society for Immunotherapy of Cancer (SITC) brought together a team of experts in immuno-oncology to create a conceptual framework for potential value in phase III studies evaluating immunotherapy combinations. The framework, put forth as a checklist ...
0 comments
There is a national crisis slowing clinical research due to staffing shortages, administrative burden and current clinical trial business models. Towards creating solutions, the Society for Immunotherapy of Cancer (SITC) hosted the Crisis in Clinical Research Virtual Summit on Wednesday, Aug. 17, from 10:00 a.m.–3:30 p.m. EDT. Attendees included oncologists, administrators, the National Cancer Institute (NCI), the US Food and Drug Administration (FDA), ...
0 comments
The number of cellular and gene therapy-based oncology treatments being developed has grown exponentially over the past ten years. Towards continuing momentum, the Society for Immunotherapy of Cancer (SITC) hosted the Cellular Therapy Regulatory Summit to define hurdles causing delays in development and regulatory review of these important products, as well as provide actionable solutions. The results of this summit are detailed in this newly released ...
0 comments
SITC is pleased to announce the publication of our newest guideline, "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer." Clinicians will find this guideline an invaluable resource to assist in navigating the challenging issues that sometimes arise during the treatment of advanced nonmelanoma skin cancer, including treatment selection, immunosuppressed patient ...
0 comments